Omar A. Albanyan

Internal Medicine

804 Service Rd # A225
East Lansing, MI 48824

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Blinatumomab and ponatinib with central nervous system treatment intensification for adolescents and young adults with Philadelphia-positive B-cell acute lymphoblastic leukemia.

Blinatumomab and ponatinib with central nervous system treatment intensification for adolescents and young adults with Philadelphia-positive B-cell acute lymphoblastic leukemia.

Journal: Haematologica

Published: April 16, 2026

Blood Stream Infections due to Candida Species: Prevalence, Risk Factors, Mortality, and Susceptibility Profile Over 3-Year Period: A Single Center Study.

Blood Stream Infections due to Candida Species: Prevalence, Risk Factors, Mortality, and Susceptibility Profile Over 3-Year Period: A Single Center Study.

Journal: International journal of microbiology

Published: January 08, 2026

Real-world outcomes of Axicabtagene Ciloleucel CAR-T therapy in large B-cell lymphoma: a single-center observational study.

Real-world outcomes of Axicabtagene Ciloleucel CAR-T therapy in large B-cell lymphoma: a single-center observational study.

Journal: Cytotherapy

Published: October 21, 2025

Impact of Obesity and Weight-Based Chemotherapy Dosing Adjustments on Outcomes of Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia.

Impact of Obesity and Weight-Based Chemotherapy Dosing Adjustments on Outcomes of Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia.

Journal: Transplantation and cellular therapy

Published: July 27, 2025

Prognostic Factors and Real-World Outcomes in Adolescents and Young Adults (AYA) With Philadelphia-Negative Acute Lymphoblastic Leukemia (ALL) Treated With the AYA-15 Protocol: A Retrospective Cohort Study From a Tertiary Care Referral Center in the Middle East.

Prognostic Factors and Real-World Outcomes in Adolescents and Young Adults (AYA) With Philadelphia-Negative Acute Lymphoblastic Leukemia (ALL) Treated With the AYA-15 Protocol: A Retrospective Cohort Study From a Tertiary Care Referral Center in the Middle East.

Journal: Clinical lymphoma, myeloma & leukemia

Published: June 05, 2025

Melphalan Dose in Combination With Fludarabine Affects Gastrointestinal Toxicity and Graft-Versus-Host Disease After Allogeneic Transplantation in Acute Myeloid Leukemia and Myelodysplastic Syndromes.

Melphalan Dose in Combination With Fludarabine Affects Gastrointestinal Toxicity and Graft-Versus-Host Disease After Allogeneic Transplantation in Acute Myeloid Leukemia and Myelodysplastic Syndromes.

Journal: Transplantation and cellular therapy

Published: June 09, 2024

Severe hematotoxicity after CD19 CAR-T therapy is associated with suppressive immune dysregulation and limited CAR-T expansion.

Severe hematotoxicity after CD19 CAR-T therapy is associated with suppressive immune dysregulation and limited CAR-T expansion.

Journal: Science advances

Published: September 22, 2023

The CAR-HEMATOTOX score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following brexucabtagene autoleucel for relapsed or refractory MCL.

The CAR-HEMATOTOX score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following brexucabtagene autoleucel for relapsed or refractory MCL.

Journal: American journal of hematology

Published: March 07, 2023

Inferior Outcomes of EU Versus US Patients Treated With CD19 CAR-T for Relapsed/Refractory Large B-cell Lymphoma: Association With Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization, and CAR-T Product Use.

Inferior Outcomes of EU Versus US Patients Treated With CD19 CAR-T for Relapsed/Refractory Large B-cell Lymphoma: Association With Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization, and CAR-T Product Use.

Journal: HemaSphere

Published: October 19, 2022

The role of CAR-T cell therapy as second line in diffuse large B-cell lymphoma.

The role of CAR-T cell therapy as second line in diffuse large B-cell lymphoma.

Journal: Therapeutic advances in hematology

Published: June 28, 2022

Mindfulness in Adolescent and Young Adult (AYA) Patients Undergoing Hematopoietic Stem Cell Transplantation (HSCT): A Qualitative Study.

Mindfulness in Adolescent and Young Adult (AYA) Patients Undergoing Hematopoietic Stem Cell Transplantation (HSCT): A Qualitative Study.

Journal: Cancers

Published: April 21, 2022

Impact of Pre-transplant Induction Therapy on Outcomes of Patients Who Undergo Autologous Stem Cell Transplantation for Mantle Cell Lymphoma in First Complete Remission.

Impact of Pre-transplant Induction Therapy on Outcomes of Patients Who Undergo Autologous Stem Cell Transplantation for Mantle Cell Lymphoma in First Complete Remission.

Journal: Hematology/oncology and stem cell therapy

Published: June 11, 2021

Showing 1-12 of 15

Last Updated: 09/26/2026